CAROLYN FEGENBUSH: Open Payments
NPI 1629009790 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$457 in 22 payments from 9 companies in 2025. Trend: 2023 $184 · 2024 $120 · 2025 $457
Food & beverage: $457
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $109 |
| Tris Pharma Inc | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Alkermes, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $20 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $15 |
Products named: CAPLYTA, Dyanavel XR, REXULTI, Auvelity, UZEDY, ARISTADA, TRINTELLIX, MAVYRET.
Industry payments across IN — which companies pay providers there.
